FDA Approves Expanded Indication for Telix ’s Illuccix to Include Patient Selection for PSMA-Directed Radioligand Therapy

Indianapolis, IN (United States) | 16 March 2023 -- Telix Pharmaceuticals today announces that the United States Food and Drug Administration (FDA) has approved a supplementary New Drug Application (sNDA) for Illuccix® (kit for the preparation...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news